(Q27851423)

13 November 2016

title

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

1 reference

Zeev Estrov

0 references

Jorge Eduardo Cortes

Jorge Cortes

0 references

Marina Konopleva

Marina Konopleva

0 references

Michael Andreeff

Michael Andreeff

0 references

Teresa S McQueen

Teresa McQueen

0 references

Xiaoyang Ling

Xiaoyang Ling

0 references

author name string

Weiguo Zhang

0 references

Yue-xi Shi

0 references

David Harris

0 references

Alfonso Quintás-Cardama

0 references

Donald Small

Journal of the National Cancer Institute

0 references

language of work or name

English

0 references

publication date

6 February 2008

0 references

published in

0 references

volume

100

0 references

issue

0 references

page(s)

184-98

0 references

cites work

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Antitumor activity of sorafenib in FLT3-driven leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Rsk1 mediates a MEK-MAP kinase cell survival signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328

Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJM328